A generic beginning with BD means what about active ingredients?

• A. Active ingredients documented bioequivalence problems
• B. Data insufficient to determine therapeutic equivalence
• C. Equivalent classification by FDA
• D. Safe to dispense

Answer: (A)

The main idea is that prefixes in generic names can signal regulatory information about bioequivalence. A generic name that begins with BD indicates there are documented bioequivalence problems with the active ingredients. That flags that the generic product has evidence showing it may not behave the same as the reference product in the body, which can affect how well it works or its safety. Because of that, you wouldn’t assume it’s therapeutically equivalent to the brand product. It’s not that there’s simply not enough data, nor that it’s automatically approved by the FDA as equivalent, nor that it’s always safe to dispense without considering this BE status.